A specific aim was to investigate the evidence for the use of these molecular profiling assays in the setting of either node-negative or node-positive ER-positive/HER2-negative breast cancer patients in guiding clinical decisions to withhold or offer adjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.